Abstract
Aim:
The effect of cyclosporine A (CsA) on hepatitis B virus (HBV) replication was investigated, and proteomics expression differentiation after CsA treatment was studied in order to provide clues to explore the effect of CsA on HBV replication.
Methods:
Methyl thiazolyl tetrazolium (MTT) assay was used to evaluate the cytotoxicity of CsA. The HBV replication level in the HBV genomic DNA transfected HepG2.2.15 cell line was determined by an ELISA analysis of hepatitis B surface antigens (HBsAg) and Hepatitis B e antigens (HBeAg) in culture supernatant, while the intracellular HBV DNA replication level was analyzed by slot blot hybridization. Two-dimensional electrophoresis was used to investigate the alteration of protein expression in HepG2.2.15 after CsA treatment in vitro. The differentially-expressed proteins were identified by Matrix-assisted laser desorption/ionization-time of flight mass spectrometry combined with an online database search.
Results:
CsA was able to inhibit the expression of HBsAg, HBeAg, and HBV DNA replication in vitro in a dose-dependent manner. A proteomics analysis indicated that the expression of 17 proteins changed significantly in the CsA treatment group compared to the control group. Eleven of the 17 proteins were identified, including the overexpression of eukaryotic translation initiation factors (eIF) 3k, otubain 1, 14.3.3 protein, eIF2-1α, eIF5A, and the tyrosine 3/tryptophan 5-mono-oxygenase activation protein in CsA-treated HepG2.2.15 cells. The downregulation of the ferritin light subunit, erythrocyte cytosolic protein of 51 kDa (ECP-51), stathmin 1/oncoprotein, adenine phosphoribosyl-transferase, and the position of a tumor protein, translationally-controlled 1, was shifted, suggesting it had undergone posttranslational modifications.
Conclusion:
Our study identified the inhibitory effect of CsA on HBV replication, and found that a group of proteins may be responsible for this inhibitory effect.
Similar content being viewed by others
Article PDF
References
Beasley RP, Lin CC, Hwang LY, Chien CS . Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet 1981; 21: 1129–33.
Ganem D, Varmus HE . The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651–93.
Rahmani Z, Huh KW, Lasher R, Siddiqui A . Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J Virol 2000; 74: 2840–6.
Bouchard MJ, Wang LH, Schneider RJ . Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001; 294: 2376–8.
Bouchard MJ, Puro RJ, Wang LH, Schneider RJ . Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol 2003; 77: 7713–9.
Sells MA, Chen ML, Acs G . Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005–9.
Sells MA, Zelent AZ, Shvartsman M, Acs G . Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol 1988; 62: 2836–44.
Broekemeier KM, Dempsey ME, Pfeiffer DR . Cyclosporine A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 1989; 264: 7826–30.
Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, Wheeler CH, et al. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 2000; 21: 3666–72.
Halestrap AP, McStay GP, Clarke SJ . The permeability transition pore complex: another view. Biochimie 2002; 84: 153–66.
Waldmeier PC, Feldtrauer JJ, Qian T, Lemasters JJ . Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporine derivative NIM811. Mol Pharmacol 2002; 62: 22–9.
Reuther GW, Pendergast AM . The roles of 14-3-3 proteins in signal transduction. Vitam Horm 1996; 52: 149–75.
Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ . Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619–28.
Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD . ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 1998; 19: 175–8.
Lopez-Girona A, Furnari B, Mondesert O, Russell P . Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 1999; 397: 172–5.
Seimiya H, Sawada H, Muramatsu Y, Shimizu M, Ohko K, Yamane K, et al. Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J 2000; 19: 2652–61.
Kino T, Gragerov A, Valentin A, Tsopanomihalou M, Ilyina-Gragerova G, Erwin-Cohen R, et al. Vpr protein of human immunodeficiency virus type-1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Virol 2005; 79: 2780–7.
Aoki H, Hayashi J, Moriyama M, Arakawa Y, Hino O . Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. J Virol 2000; 74: 1736–41.
Ku NO, Liao J, Omary MB . Phosphorylation of human keratin 18 serine 33 regulates binding to 14-3-3 proteins. EMBO J 1998; 17: 1892–906.
Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, et al. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 1997; 91: 961–71.
Diao J, Khine AA, Sarangi F, Hsu E, Iorio C, Tibbles LA, et al. X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem 2000; 276: 8328–40.
Matsuda S, Koyasu S . Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119–25.
Chow CW, Davis R . Integration of calcium and cyclic AMP signaling pathways by 14-3-3. Mol Cel Biol 2000; 20: 702–12.
Hanash SM, Strahler JR, Kuick R, Chu EH, Nichols D . Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem 1988; 263: 12813–5.
Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A, et al. Overexpressioin of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 2000; 82: 142–50.
Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, et al. The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 2000; 18: 722–30.
Li C, Tan YX, Zhou H, Ding SJ, Li SJ, Ma DJ, et al. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: identification of potential tumor markers. Proteomics 2005; 5: 1125–39.
McKinsey TA, Zhang CL, Olson EN . Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulindependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA 2000; 97: 14400–5.
Ben-Neriah Y . Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002; 3: 20–6.
Wilkinson KD . Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 1997; 11: 1245–56.
Balakirev MY, Tcherniuk SO, Jaquinod M, Chroboczek J, Otubains: a new family of cysteine proteases in the ubiquitin pathway. EMBO J 2003; 4: 517–22.
Soares L, Seroogy C, Skrenta H, Anandasabapathy N, Lovelace P, Chung CD, et al. Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nat Immunol 2004; 5: 45–54.
Cenciarelli C, Hou D, Hsu KC, Rellahan BL, Wiest DL, Smith HT, et al. Activation-induced ubiquitination of the T cell antigen receptor. Science 1992; 257: 795–7.
Davis DL, Soldin SJ . Identification of ubiquitin as an immunophilin. Biochem Biophys Res Commun 2000; 277: 325–9.
Asano K, Clayton J, Shalev A, Hinnebusch AG . A multifactor complex of eukaryotic initiation factors, eIF1, eIF2, eIF3, eIF5, and initiator tRNAMet is an important translation initiation intermediate in vivo. Genes Dev 2000; 14: 2534–46.
Proud CG . eIF2 and the control of cell physiology. Semin Cell Dev Biol 2005; 16: 3–12.
Bevec D, Jaksche H, Oft M, Wohl T, Himmelspach M, Pacher A, et al. Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A. Science 1996; 271: 1858–60.
Hauber I, Bevec D, Heukeshoven J, Kratzer F, Horn F, Choidas A, et al. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 2005; 115: 76–85.
Robinson WS, Miller RH, Marion PL . Hepadnaviruses and retroviruses share genome homology and features of replication. Hepatology 1987; 7: S64–73.
Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, Bommer UA . The growth-related, translationally controlled protein P23 has properties of a tubulin binding proterin and associates transiently with microtubules during the cell cycle. J Cell Sci 1999; 112: 1257–71.
Bommer UA, Thiele BJ . The translationally controlled tumor protein (TCTP). Int J Biochem Cell Biol 2004; 36: 379–85.
Sanchez JC, Schaller D, Ravier F, Golaz O, Jaccoud S, Belet M, et al. Translationally controlled tumor protein: a protein identified in several nontumoral cells including erythrocytes. Electrophoresis 1997; 18: 150–5.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Basic Research Program 973 from the Ministry of Science and Technology in China (No 2003CB515501).
Rights and permissions
About this article
Cite this article
Xie, Hy., Xia, Wl., Zhang, Cc. et al. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment. Acta Pharmacol Sin 28, 975–984 (2007). https://doi.org/10.1111/j.1745-7254.2007.00590.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00590.x
Keywords
This article is cited by
-
Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia
International Journal of Hematology (2017)